PGDH Antibody (H-3): sc-271418

PGDH Antibody (H-3) is a mouse monoclonal IgG1 kappa light chain antibody that detects PGDH protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). PGDH (H-3) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. PGDH plays a crucial role in prostaglandin degradation, which are lipid compounds involved in numerous physiological processes, including inflammation and blood flow regulation. Through oxidation of the 15-hydroxyl group of prostaglandins to a keto group, PGDH significantly reduces these molecules′ biological activity, modulating their effects in the body. This enzymatic activity is particularly important during pregnancy, where prostaglandin balance can influence various outcomes. Cortisol has been shown to inhibit PGDH activity in human placental cells, which can have implications for conditions such as preeclampsia, where altered levels of cortisol and PGDH may contribute to the disorder′s pathophysiology. Understanding PGDH function and regulatory mechanisms is essential for developing therapeutic strategies targeting prostaglandin-related conditions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PGDH Antibody (H-3) References:

1. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder.  |  Gee, JR., et al. 2003. Urol Oncol. 21: 266-70. PMID: 12954496
2. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.  |  Ding, Y., et al. 2005. Carcinogenesis. 26: 65-72. PMID: 15358636
3. Regulation of 15-hydroxyprostaglandin dehydrogenase (PGDH) gene activity, messenger ribonucleic acid processing, and protein abundance in the human chorion in late gestation and labor.  |  Johnson, RF., et al. 2004. J Clin Endocrinol Metab. 89: 5639-48. PMID: 15531523
4. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.  |  Backlund, MG., et al. 2005. J Biol Chem. 280: 3217-23. PMID: 15542609
5. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.  |  Yan, M., et al. 2004. Proc Natl Acad Sci U S A. 101: 17468-73. PMID: 15574495
6. Key NAD+-binding residues in human 15-hydroxyprostaglandin dehydrogenase.  |  Cho, H., et al. 2005. Arch Biochem Biophys. 433: 447-53. PMID: 15581601
7. 15-Hydroxyprostaglandin dehydrogenase can be induced by dexamethasone and other glucocorticoids at the therapeutic level in A549 human lung adenocarcinoma cells.  |  Tong, M. and Tai, HH. 2005. Arch Biochem Biophys. 435: 50-5. PMID: 15680906
8. Understanding human 15-hydroxyprostaglandin dehydrogenase binding with NAD+ and PGE2 by homology modeling, docking and molecular dynamics simulation.  |  Hamza, A., et al. 2005. Bioorg Med Chem. 13: 4544-51. PMID: 15908215
9. Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength.  |  Palla, AR., et al. 2021. Science. 371: PMID: 33303683
10. Downregulation of 15-PGDH enhances MASH-HCC development via fatty acid-induced T-cell exhaustion.  |  Hu, X., et al. 2023. JHEP Rep. 5: 100892. PMID: 37942226
11. Localisation of 15-hydroxy prostaglandin dehydrogenase (PGDH) and steroidogenic enzymes in the equine placenta.  |  Han, X., et al. 1995. Equine Vet J. 27: 334-9. PMID: 8654347
12. Immunoreactive 15-hydroxyprostaglandin dehydrogenase (PGDH) is reduced in fetal membranes from patients at preterm delivery in the presence of infection.  |  Van Meir, CA., et al. 1996. Placenta. 17: 291-7. PMID: 8829211

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-PGDH Antibody (H-3) has 3 citations in a variety of scientific publications.

Primary antibodies like Anti-PGDH Antibody (H-3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

PGDH Antibody (H-3) Specifications

Alternate Product Name: PGDH

Product Clone Name: H-3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1-263

Epitope Target: PGDH

Epitope Species: human

Product Reactivity/Detection: PGDH

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 3 citations in various scientific publications

Available Conjugates/Forms for PGDH Antibody (H-3): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin